An interventional study of colon-rectal resection in Ovary Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 28 open to participants now, 32 under way, none of them phase 3. Ovarian Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Among the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 8 that started in 2025, is one of 13 with no phase, reaches primary completion later than 28 of the 31 other live ones, and was the 27th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.
Browse Ovarian Neoplasms studies →28 of the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–99 · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
By country, each count listing its studies:
Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 395 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 53 across the 18 interventional studies, 160 across the 22 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
7 of the studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07546578Fondazione Policlinico Universitario Agostino Gemelli IRCCSSetting Up ctDNA Analysis on Archived Plasma Samples | 2026-11 |
| NCT07070973Fondazione Policlinico Universitario Agostino Gemelli IRCCSProactive Hemodynamic Management During Cytoreductive Surgery and HIPEC | 2026-11-30 |
| NCT05769517Fondazione Policlinico Universitario Agostino Gemelli IRCCSPrediction of Germline BRCA 1/2 Genes From Healthy Ovaries | 2026-12-31 |
| NCT07808320Fondazione Policlinico Universitario Agostino Gemelli IRCCSHERCULES: Ultrasound-Based Liver Involvement Classification in Ovarian Cancer | 2027-01 |
| NCT07645716Fondazione Policlinico Universitario Agostino Gemelli IRCCSEvaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology | 2027-01-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 40 studies in Ovarian Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Resection of the sigmoid-rectum is a procedure frequently required in cytoreductive surgery for advanced ovarian cancer, and it is also among the procedures with the highest risk of complications. One of the major, albeit uncommon, complications of intestinal anastomosis is anastomotic leakage. According to the literature, the rate of anastomotic leakage following cytoreductive surgery for ovarian cancer ranges from 1.7% to 17%.
The risk factors associated with this complication are varied and often inconsistent across studies. They range from preoperative clinical conditions-such as age, low albumin levels, and Body Mass Index \< 18-to intraoperative factors such as low to mid rectal resection, high ligation of the inferior mesenteric artery, and multiple bowel resections.
Apart from the rehabilitative programs introduced by the Enhanced Recovery After Surgery protocol-which aim to improve the nutritional status of patients undergoing cytoreductive surgery for ovarian cancer-we currently lack validated tools to reduce the risk of leakage. The most commonly used strategy remains the creation of a protective stoma. However, several studies have shown that this procedure is not actually a protective factor against anastomotic leakage; rather, its utility lies in mitigating the severity of the complication.
Nonetheless, stomas have a significant clinical and psychological impact, with complication rates ranging from 33.9% to 45% and reversal rates between 66.5% and 89%.
This study aims to evaluate the feasibility of a no-stoma strategy in a selected "low-risk" population for anastomotic leakage among patients undergoing cytoreductive surgery for primary or recurrent ovarian cancer. Focusing on the goal of achieving a zero stoma rate, the study will provide valuable insights into the utility and outcomes of stoma creation. The results will support more informed and patient-centered clinical decisions in the management of ovarian cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients women who underwent colon rectal resection
Procedure: colon-rectal resection
The patients who underwent colon rectal resection, would be evaluated for stomia or not.
Rate of Anastomotic Dehiscence in Low-Risk Patients Undergoing Primary or Secondary Cytoreductive Surgery for Ovarian, Fallopian Tube, or Peritoneal Tumors
The feasibility of a no-stoma policy will be assessed by calculating the rate of anastomotic dehiscence in low-risk patients (who therefore did not receive a diverting stoma) and comparing these results with published data from the literature.
Time frame: Intraoperative and postoperative follow-up period (90 days postoperative)
Risk Factors for Anastomotic Leak
Identification of preoperative and intraoperative variables associated with anastomotic leak using a multivariable logistic regression model.
Time frame: preoperative, intraoperative
Rate of Occult Anastomotic Leak in Patients With Diverting Ostomy
Proportion of asymptomatic patients with diverting ostomy presenting with occult anastomotic leak, as assessed by water-soluble rectal contrast enema performed between postoperative days 5 and 10.
Time frame: Postoperative days up to 20.
Management Strategies for Anastomotic Leak
Description and distribution of management strategies for anastomotic leak (conservative vs. non-conservative), stratified by low- and high-risk patient groups, and evaluation of the role of ostomy in leak management.
Time frame: Postoperative period (up to 90 days).
Impact of Bowel Surgery on Quality of Life
Change in quality of life and bowel function, as measured by: Gastrointestinal Quality of Life Index (GIQLI) in all patients STOMA questionnaire in patients with diverting ostomy Low Anterior Resection Syndrome (LARS) score Knowles-Eccersley-Scott-Symptom (KESS) questionnaire All questionnaires will be administered preoperatively and at 3 and 6 months post-surgery.
Time frame: Baseline (pre-surgery), 3 months, and 6 months post-surgery.
Started May 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.
Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 37 months is below that.
Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →